Clene Nanomedicine
Clinical trials sponsored by Clene Nanomedicine, explained in plain language.
-
New hope for ALS patients: experimental drug made available through expanded access
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers early access to an experimental drug called CNM-Au8 for people with amyotrophic lateral sclerosis (ALS), a serious nerve disease. Participants must be 18 or older and have a confirmed ALS diagnosis. The goal is to provide treatment while more research is done,…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 26, 2026 03:18 UTC
-
ALS patients get expanded access to experimental gold nanocrystal therapy
Disease control NO_LONGER_AVAILABLEThis program gave up to 300 people with amyotrophic lateral sclerosis (ALS) access to an experimental drug called CNM-Au8. The main goal was to provide treatment, not to test if it works. Researchers also tracked safety by monitoring side effects. The program is no longer availab…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New MS drug made available early to patients in need
Disease control TEMPORARILY_NOT_AVAILABLEThis program offers early access to an experimental drug called CNM-Au8 for up to 25 adults with multiple sclerosis (MS). It is for people who have relapsing MS, non-active secondary progressive MS, or primary progressive MS. The goal is to provide treatment before the drug is fu…
Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 26, 2026 03:08 UTC
-
ALS patients get extended access to experimental drug in safety Follow-Up
Disease control OngoingThis study is for people with early-stage ALS who finished a previous trial of the experimental drug CNM-Au8. It aims to check the long-term safety of the treatment, not to cure the disease. About 40 participants will receive the drug openly, and researchers will monitor side eff…
Phase: PHASE2 • Sponsor: Clene Nanomedicine • Aim: Disease control
Last updated May 26, 2026 03:04 UTC